Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Other Non-Current Liabilities (2018 - 2026)

Ocular Therapeutix has reported Other Non-Current Liabilities over the past 11 years, most recently at $909000.0 for Q1 2026.

  • For Q1 2026, Other Non-Current Liabilities rose 531.25% year-over-year to $909000.0; the TTM value through Mar 2026 reached $909000.0, up 531.25%, while the annual FY2025 figure was $13.9 million, 9760.28% up from the prior year.
  • Other Non-Current Liabilities for Q1 2026 was $909000.0 at Ocular Therapeutix, down from $13.9 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $30.0 million in Q4 2023 and troughed at $117000.0 in Q3 2024.
  • A 5-year average of $10.6 million and a median of $11.6 million in 2022 define the central range for Other Non-Current Liabilities.
  • Biggest five-year swings in Other Non-Current Liabilities: crashed 99.53% in 2024 and later surged 12688.03% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $6.4 million in 2022, then soared by 372.16% to $30.0 million in 2023, then crashed by 99.53% to $141000.0 in 2024, then surged by 9760.28% to $13.9 million in 2025, then tumbled by 93.46% to $909000.0 in 2026.
  • Business Quant data shows Other Non-Current Liabilities for OCUL at $909000.0 in Q1 2026, $13.9 million in Q4 2025, and $15.0 million in Q3 2025.